Literature DB >> 18805196

A novel approach to positron emission tomography in lung cancer.

Susan D Moffatt-Bruce1, Stephen P Povoski, Suhail Sharif, Nathan C Hall, Patrick Ross, Morgan A Johnson, Edward W Martin.   

Abstract

18F-fluorodeoxyglucose positron emission tomography-computed tomography is integral to the staging of lung cancer. We describe the combined use of diagnostic preoperative 18F-fluorodeoxyglucose positron emission tomography-computed tomography, intraoperative 18F-fluorodeoxyglucose handheld gamma probe detection, and immediate postoperative 18F-fluorodeoxyglucose positron emission tomography-computed tomography patient and specimen imaging for improved staging and determination of adequacy of mediastinal lymph node dissection.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18805196     DOI： 10.1016/j.athoracsur.2008.03.072

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN： 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

2.  Cerenkov luminescence endoscopy: improved molecular sensitivity with β--emitting radiotracers.

Authors:  Colin M Carpenter; Xiaowei Ma; Hongguang Liu; Conroy Sun; Guillem Pratx; Jing Wang; Sanjiv S Gambhir; Lei Xing; Zhen Cheng
Journal:  J Nucl Med       Date:  2014-10-09       Impact factor: 10.057

3.  Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Andrew Z Chow; Jay R Gaglani; Eamonn E Bahnson; Cathy M Mojzisik; Maureen P Kuhrt; Charles L Hitchcock; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2011-11-23       Impact factor: 2.754

4.  Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Chadwick L Wright; Edward W Martin
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

Review 5.  Nuclear-medicine probes: Where we are and where we are going.

Authors:  Andrea Gonzalez-Montoro; Cesar David Vera-Donoso; Georgios Konstantinou; Pablo Sopena; Manolo Martinez; Juan Bautista Ortiz; Montserrat Carles; Jose Maria Benlloch; Antonio Javier Gonzalez
Journal:  Med Phys       Date:  2022-05-20       Impact factor: 4.506

6.  Intraoperative detection of ¹⁸F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria.

Authors:  Stephen P Povoski; Gregg J Chapman; Douglas A Murrey; Robert Lee; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2013-03-04       Impact factor: 4.430

7.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

8.  Comparison of two threshold detection criteria methodologies for determination of probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery.

Authors:  Gregg J Chapman; Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Robert Lee; Edward W Martin
Journal:  BMC Cancer       Date:  2014-09-13       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.